Chrysant Steven G
a Department of Cardiology , University of Oklahoma College of Medicine , Oklahoma City , OK , USA.
Postgrad Med. 2018 Mar;130(2):159-165. doi: 10.1080/00325481.2018.1433434. Epub 2018 Feb 1.
Systolic hypertension, especially isolated systolic hypertension (ISH) is very common in older subjects aged ≥ 65 years and is a major risk factor for cardiovascular disease (CVD), strokes, heart failure (HF) and chronic kidney disease (CKD). It is also, directly and linearly related with these complications irrespective of sex, or ethnicity, but it is worse with the advancement of age. Effective control of systolic blood pressure (SBP), is associated with significant reduction in the incidence of these complications. Currently, there is a debate about the optimal SBP control in view of the Systolic Blood Pressure Intervention Trial (SPRINT) showing beneficial cardiovascular (CV) effects of intensive SBP of < 120 mmHg in older patients. Also, the recently released blood pressure (BP) guidelines by the American College of Cardiology, the American Heart Association and the American Society of Hypertension (ACC/AHA/ASH) recommend a SBP reduction of < 130 mmHg. These SBP treatment recommendations are in contrast with the current (JNC VIII) committee of BP treatment guidelines, which recommend a SBP reduction < 150 mmHg for the same age of patients. All these different recommendations have created a debate regarding the optimal treatment targets for the systolic hypertension of the elderly patients. To gain more information a focused Medline search was conducted from 2010 to 2017 using the terms, systolic blood pressure, aggressive control, older subjects, treatment guidelines, and 37 pertinent papers were retrieved. The findings from these studies suggest a SBP reduction of < 140 mm Hg for persons aged ≥ 60 years, with an attempt for SBP reduction to ≤130 mm Hg in healthier subjects and hose with CVD, DM, and CKD. Care should be taken not to further reduce the SBP in older subjects if their DBP is ≤60 mmHg for the fear of J-curve effect.
收缩期高血压,尤其是单纯收缩期高血压(ISH)在65岁及以上的老年人群中非常常见,是心血管疾病(CVD)、中风、心力衰竭(HF)和慢性肾脏病(CKD)的主要危险因素。无论性别或种族如何,它也与这些并发症直接呈线性相关,但随着年龄的增长情况会更糟。有效控制收缩压(SBP)与这些并发症的发生率显著降低相关。目前,鉴于收缩压干预试验(SPRINT)显示强化收缩压<120 mmHg对老年患者有有益的心血管(CV)效应,关于最佳收缩压控制存在争议。此外,美国心脏病学会、美国心脏协会和美国高血压学会(ACC/AHA/ASH)最近发布的血压(BP)指南建议将收缩压降低至<130 mmHg。这些收缩压治疗建议与当前(JNC VIII)血压治疗指南委员会的建议形成对比,后者建议同年龄段患者的收缩压降低至<150 mmHg。所有这些不同的建议引发了关于老年患者收缩期高血压最佳治疗目标的争论。为获取更多信息,于2010年至2017年使用收缩压、积极控制、老年受试者、治疗指南等术语在Medline进行了针对性检索,共检索到37篇相关论文。这些研究的结果表明,60岁及以上人群的收缩压应降低至<140 mmHg,对于更健康的受试者以及患有CVD、DM和CKD的患者,应尝试将收缩压降低至≤130 mmHg。如果老年受试者的舒张压≤60 mmHg,应注意不要进一步降低其收缩压,以免出现J曲线效应。